Print

AVEG 004A

A Phase I Multicenter Clinical Trial to Evaluate the Safety and Immunogenicity of Vaccinia Derived HIV-1 Recombinant Envelope Glycoprotein (gp160) of Human Immunodeficiency Virus: Evaluation of 200 microgram Dose

Trial Details:

I Completed
National Institute of Allergy and Infectious Diseases (NIAID) August 04, 1992
gp160 Vaccine (Immuno-AG) Protein gp160 env B LAI, MN
gp160 Vaccine (Immuno-AG) Protein
USA 25
NCT00001056
http://clinicaltrials.gov/ct2/show/NCT00001056